Skip to main content
NewslettersWatchlist

Replicel Life Sciences Inc(RP-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.010
Day High0.015
Open:0.010
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Replicel Life Sciences Inc

Select a category then submit the form to load news
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 25 Undervalued TSX Venture Exchange Stocks (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 25 Undervalued TSX Venture Exchange Stocks (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
PR Newswire
Canadian Investment Regulatory Organization Trade Resumption - RP
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 25 Undervalued TSX Venture Exchange Stocks (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
AI-generated - The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
Business Wire
RealPage Awarded 2023 ENERGY STAR Partner of the Year for Sustained Excellence
The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
ACCESS Newswire
RepliCel Provides Corporate Update
The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Stocks (RP)
The Globe and Mail
RepliCel Life Sciences: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (RP)
ACCESS Newswire
RepliCel Announces Material Patent Milestones in Key Markets
ACCESS Newswire
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
ACCESS Newswire
RepliCel’s Manufacturing Inspected by Japan’s PMDA
ACCESS Newswire
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
ACCESS Newswire
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
ACCESS Newswire
RepliCel Announces Material Patent Milestones
ACCESS Newswire
RepliCel Closed Final Tranche of Strategic Investment Commitment
ACCESS Newswire
RepliCel Terminates License Agreement with Shiseido
Business Wire
RealPage Agrees to Acquire HomeWiseDocs, The Premier Provider of Disclosure Management Services to the Community Association Industry
ACCESS Newswire
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
ACCESS Newswire
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
ACCESS Newswire
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
ACCESS Newswire
RepliCel Announces Dermal Injector Update
ACCESS Newswire
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents

Profile

RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from the Licensing fees.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.